LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 9 von insgesamt 9

Suchoptionen

Artikel: SARS-CoV-2 and probable lung cancer risk.

Khiali, Sajad / Rezagholizadeh, Afra / Entezari-Maleki, Taher

2022 Band 12, Heft 3, Seite(n) 291–292

Abstract: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global crisis with a growing number of mortalities and morbidities worldwide. Despite performing numerous researches, there are still considerable unrevealed ... ...

Abstract	The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global crisis with a growing number of mortalities and morbidities worldwide. Despite performing numerous researches, there are still considerable unrevealed details regarding the long-term complications and post-infection immunity of the coronavirus disease 2019 (COVID-19). Based on pathophysiological features, SARS-CoV-2 may act similarly as an oncovirus in the lung. This letter summarized three possible oncogenic mechanisms of SARS-CoV-2 that may be associated with lung cancer development.
Sprache	Englisch
Erscheinungsdatum	2022-03-26
Erscheinungsland	Iran
Dokumenttyp	Journal Article
ZDB-ID	2604624-6
ISSN	2228-5660 ; 2228-5652
ISSN (online)	2228-5660
ISSN	2228-5652
DOI	10.34172/bi.2022.23266
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Evaluation of the activated partial thromboplastin time and its influential factors in ischemic heart disease patients under heparin treatment.

Rezagholizadeh, Afra / Adib, Zainab-Kubra / Entezari-Maleki, Taher

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

2021 Band 32, Heft 7, Seite(n) 496–503

Abstract: This study aimed to detect the defects of the current methods used to monitor unfractionated heparin (UFH) anticoagulant effect and find possible assistive parameters for activated partial thromboplastin time (aPTT) test to improve treatment performance. ...

Abstract	This study aimed to detect the defects of the current methods used to monitor unfractionated heparin (UFH) anticoagulant effect and find possible assistive parameters for activated partial thromboplastin time (aPTT) test to improve treatment performance. The required information was gathered from patients' case records, treatment charts and laboratory reports. Kendall's tau correlation coefficient was calculated for analysing the relationship between variables. The partial least squares (PLS) and the stepwise multiple regression were operated, and the area under the receiver operating characteristic curve (AUC) and the r-squared (r2) were used to show the analytical ability of the models, respectively. Overall, 102 UFH-receiving ischemic heart disease patients participated in this study. The aPTT value varied from 30 to 95 s (mean ± SD = 44 ± 14). Therapeutic aPTT values were observed in 15% of hospitalization days. The aPTT value showed statistically significant correlations with mean UFH infusion (U/kg/h), age, prothrombin time (PT), smoking, international normalized ratio, haemoglobin (Hgb) and blood triglyceride level. Triglyceride level and PT were efficacious predictors of aPTT value (P < 0.001, r2 = 0.336). Moreover, blood urea nitrogen (BUN) and blood creatinine (Cr) levels were the best predictors for mortality. The mean BUN/Cr ratio was 18 ± 5 and 25 ± 12 in nonexpired and expired subjects, respectively. If calibrated institution-specific therapeutic aPTT ranges and updated weight-based UFH nomograms get employed, aPTT test, along with the BUN/Cr ratio and Hgb level, as assistive parameters for predicting haemorrhagic incidents, would be near ideal monitoring method in UFH-receiving patients.
Mesh-Begriff(e)	Adult ; Aged ; Aged, 80 and over ; Anticoagulants/therapeutic use ; Blood Coagulation/drug effects ; Female ; Heparin/therapeutic use ; Humans ; Male ; Middle Aged ; Myocardial Ischemia/blood ; Myocardial Ischemia/drug therapy ; Partial Thromboplastin Time ; Prospective Studies
Chemische Substanzen	Anticoagulants ; Heparin (9005-49-6)
Sprache	Englisch
Erscheinungsdatum	2021-10-10
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	1033551-1
ISSN	1473-5733 ; 0957-5235
ISSN (online)	1473-5733
ISSN	0957-5235
DOI	10.1097/MBC.0000000000001088
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2920: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Current evidence of COVID-19 vaccination-related cardiovascular events.

Khiali, Sajad / Rezagholizadeh, Afra / Behzad, Hossein / Bannazadeh Baghi, Hossein / Entezari-Maleki, Taher

Postgraduate medicine

2023 Band 135, Heft 2, Seite(n) 102–120

Abstract: Currently, the world is recovering from the shock of the coronavirus disease 2019 (COVID-19) pandemic; however, this situation is still fragile. Health authorities recommend administering COVID-19 vaccines as the safest and most reliable tool for ... ...

Abstract	Currently, the world is recovering from the shock of the coronavirus disease 2019 (COVID-19) pandemic; however, this situation is still fragile. Health authorities recommend administering COVID-19 vaccines as the safest and most reliable tool for eliminating COVID-19. Subsequent to the extensive administration of the COVID-19 vaccines, a series of cardiovascular adverse effects have been reported. This comprehensive review aimed to provide an update on the etiology, pathophysiology, clinical features, and management of the cardiovascular adverse events associated with COVID-19 vaccines, including myocarditis, pericarditis, thrombosis with thrombocytopenia syndrome, myocardial infarction, cardiac arrhythmias, hypertension, and stress-induced cardiomyopathy. The benefits of COVID-19 vaccination far outweigh the reported adverse events. It would be clinically important to provide diagnostic scoring systems to differentiate COVID-19-related cardiovascular adverse events from other causes and develop therapeutic approaches for their management. Further evaluation of cardiovascular adverse events of the COVID-19 vaccines is crucial for implementing vaccination programs and developing safer and more reliable vaccines.
Mesh-Begriff(e)	Humans ; COVID-19 ; COVID-19 Vaccines ; Vaccination ; Drug-Related Side Effects and Adverse Reactions ; Hypertension
Chemische Substanzen	COVID-19 Vaccines
Sprache	Englisch
Erscheinungsdatum	2023-01-03
Erscheinungsland	England
Dokumenttyp	Journal Article ; Review
ZDB-ID	410138-8
ISSN	1941-9260 ; 0032-5481
ISSN (online)	1941-9260
ISSN	0032-5481
DOI	10.1080/00325481.2022.2161249
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Ua VI Zs.407: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: A comprehensive review on sarilumab in COVID-19.

Khiali, Sajad / Rezagholizadeh, Afra / Entezari-Maleki, Taher

Expert opinion on biological therapy

2020 Band 21, Heft 5, Seite(n) 615–626

Abstract: ... ...

Abstract	Introduction
Mesh-Begriff(e)	Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/metabolism ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/metabolism ; Alanine/therapeutic use ; Animals ; Antibodies, Monoclonal, Humanized/metabolism ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/metabolism ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; COVID-19/epidemiology ; COVID-19/metabolism ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/epidemiology ; Cytokine Release Syndrome/metabolism ; Humans ; Pandemics ; SARS-CoV-2/drug effects ; SARS-CoV-2/metabolism
Chemische Substanzen	Antibodies, Monoclonal, Humanized ; Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; sarilumab (NU90V55F8I) ; Alanine (OF5P57N2ZX)
Schlagwörter	covid19
Sprache	Englisch
Erscheinungsdatum	2020-11-25
Erscheinungsland	England
Dokumenttyp	Journal Article ; Review
ZDB-ID	2052501-1
ISSN	1744-7682 ; 1471-2598
ISSN (online)	1744-7682
ISSN	1471-2598
DOI	10.1080/14712598.2021.1847269
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 6094: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.

Rezagholizadeh, Afra / Khiali, Sajad / Sarbakhsh, Parvin / Entezari-Maleki, Taher

European journal of pharmacology

2021 Band 897, Seite(n) 173926

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has become a global health crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as the first officially approved agent for COVID-19 treatment, we performed this ... ...

Abstract	The coronavirus disease 2019 (COVID-19) pandemic has become a global health crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as the first officially approved agent for COVID-19 treatment, we performed this systematic review and meta-analysis to evaluate the efficacy and safety of remdesivir administration in COVID-19 patients. A systematic literature search was done through MEDLINE, Google Scholar, Web of Science, Scopus, Science Direct, Cochrane Library, medRxiv, and bioRxiv from their inception to December 22nd, 2020. Five randomized controlled trials (RCTs) and five non-randomized studies of intervention (NRSI) were entered into the meta-analysis. The results showed that remdesivir administration was associated with a significant improvement in the 28-day recovery (RR = 1.09, 95%CI, 1.04-1.15), low flow oxygen support through days one to 14 (RR = 2.88, 95%CI, 1.80-4.60), and invasive mechanical ventilation or extracorporeal membrane oxygenation requirement through days 14-28 of the follow-up time (RR = 5.34, 95%CI, 2.37-12.05). The risk of experiencing serious adverse drug reactions (ADRs) was significantly lower (RR = 0.75, 95%CI, 0.63-0.90) in the remdesivir group than the comparison/control group. The pooled median difference of the time to clinical improvement was 2.99 (95%CI = 2.71-3.28), which did not remain significant during the sensitivity analysis. The clinical output comparison of the 5-day and 10-day remdesivir courses revealed that the 5-day regimen might provide similar benefits while causing fewer serious ADRs than 10-day. The current meta-analysis provided an updated evaluation of scientific evidence on the use of remdesivir in COVID-19 patients. Performing adequate well-designed RCTs are needed to show more accurate results.
Mesh-Begriff(e)	Adenosine Monophosphate/adverse effects ; Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/adverse effects ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; Humans ; Pandemics ; Randomized Controlled Trials as Topic ; Treatment Outcome
Chemische Substanzen	Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
Sprache	Englisch
Erscheinungsdatum	2021-02-04
Erscheinungsland	Netherlands
Dokumenttyp	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	80121-5
ISSN	1879-0712 ; 0014-2999
ISSN (online)	1879-0712
ISSN	0014-2999
DOI	10.1016/j.ejphar.2021.173926
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 522: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial.

Khiali, Sajad / Taban-Sadeghi, Mohammadreza / Sarbakhsh, Parvin / Khezerlouy-Aghdam, Naser / Namdar, Hossein / Salehi, Rezvanieh / Rezagholizadeh, Afra / Entezari-Maleki, Taher

Trials

2023 Band 24, Heft 1, Seite(n) 645

Abstract: Background: Patients with acute myocardial infarction are at greater risk for chronic heart failure and mortality. Currently, there is limited evidence supporting the beneficial effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular ... ...

Abstract	Background: Patients with acute myocardial infarction are at greater risk for chronic heart failure and mortality. Currently, there is limited evidence supporting the beneficial effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in non-diabetic patients with reduced left ventricular ejection fraction following acute myocardial infarction. Furthermore, the clinical effects of the combination of standard-dose sodium-glucose cotransporter-2 inhibitors with colchicine and high-dose sodium-glucose cotransporter-2 inhibitors in this setting have not been evaluated yet. Methods: A prospective, double-blinded, parallel-group, placebo control randomized trial will be carried out at Shahid Madani Heart Center, the largest teaching referral hospital for cardiovascular diseases, affiliated with Tabriz University of Medical Sciences. A total of 105 patients with reduced left ventricular ejection fraction (≤ 40%) following the first episode of ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with stent insertion will be randomized 1:1:1 to receive empagliflozin 10 mg daily, a combination of empagliflozin 10 mg daily and colchicine 0.5 mg twice daily, or empagliflozin 25 mg daily for 12 weeks. The primary outcomes are changes in the New York Heart Association functional classification and high-sensitivity C-reactive protein from the randomization through week 4 and week 12. Discussion: The present study will be the first trial to evaluate the efficacy and safety of early treatment with the combination of standard-dose empagliflozin and colchicine as well as high-dose empagliflozin in non-diabetic patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction. The results of this research will represent a significant step forward in the treatment of patients with acute myocardial infarction. Trial registration: Clinical trial ID: IRCT20111206008307N39. Registration date: 27 October 2022.
Mesh-Begriff(e)	Humans ; Stroke Volume ; Ventricular Function, Left ; ST Elevation Myocardial Infarction/diagnosis ; ST Elevation Myocardial Infarction/therapy ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Colchicine/adverse effects ; Prospective Studies ; Myocardial Infarction/diagnosis ; Myocardial Infarction/drug therapy ; Percutaneous Coronary Intervention/adverse effects ; Heart Failure/drug therapy ; Glucose/therapeutic use ; Sodium ; Randomized Controlled Trials as Topic
Chemische Substanzen	empagliflozin (HDC1R2M35U) ; Sodium-Glucose Transporter 2 Inhibitors ; Colchicine (SML2Y3J35T) ; Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27)
Sprache	Englisch
Erscheinungsdatum	2023-10-06
Erscheinungsland	England
Dokumenttyp	Clinical Trial Protocol ; Journal Article
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1745-6215
ISSN (online)	1745-6215
ISSN	1468-6694 ; 1745-6215
DOI	10.1186/s13063-023-07682-6
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review.

Khiali, Sajad / Taban-Sadeghi, Mohammadreza / Sarbakhsh, Parvin / Khezerlouy-Aghdam, Naser / Rezagholizadeh, Afra / Asham, Hila / Entezari-Maleki, Taher

Journal of clinical pharmacology

2023 Band 63, Heft 12, Seite(n) 1307–1323

Abstract: Despite the growing body of evidence regarding the beneficial cardiovascular effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors, clinical data in individuals without diabetes, heart failure (HF), and/or chronic kidney disease (CKD) is limited. ... ...

Abstract	Despite the growing body of evidence regarding the beneficial cardiovascular effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors, clinical data in individuals without diabetes, heart failure (HF), and/or chronic kidney disease (CKD) is limited. A systematic review of the literature was conducted in PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar, from database inception until May 4, 2023, to explore new evidence of SGLT2 inhibitors' cardiovascular benefits in individuals without diabetes, HF, and/or CKD. A total of 1156 individuals from 14 studies (13 randomized controlled trials and 1 nonrandomized study) were included. The results showed the benefits of SGLT2 inhibitors on blood pressure, weight, and body mass index in this population with an acceptable safety profile. The current evidence supports the potential role of SGLT2 inhibitors as primary prevention in individuals without diabetes, HF, and/or CKD. This review may shed light on the use of SGLT2 inhibitors in conditions such as stage A HF and metabolic syndrome. The literature trend is going toward uncovering SGLT2 inhibitors' role in stage B HF, different types of myocardial infarction, and cardiac arrhythmias.
Mesh-Begriff(e)	Humans ; Diabetes Mellitus, Type 2/metabolism ; Heart Failure/drug therapy ; Randomized Controlled Trials as Topic ; Renal Insufficiency, Chronic/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology
Chemische Substanzen	Sodium-Glucose Transporter 2 Inhibitors
Sprache	Englisch
Erscheinungsdatum	2023-08-02
Erscheinungsland	England
Dokumenttyp	Journal Article ; Review ; Systematic Review
ZDB-ID	188980-1
ISSN	1552-4604 ; 0091-2700 ; 0021-9754
ISSN (online)	1552-4604
ISSN	0091-2700 ; 0021-9754
DOI	10.1002/jcph.2311
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Uf I Zs.176: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel: A Comprehensive Review on Sarilumab in COVID-19

Khiali, Sajad / Rezagholizadeh, Afra / Entezari-Maleki, Taher

Abstract: Introduction: The coronavirus disease 2019 (COVID-19) pandemic, caused by a newly discovered coronavirus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2), continues to spread all around the world. Despite the emergency of COVID-19 ... ...

Abstract	Introduction: The coronavirus disease 2019 (COVID-19) pandemic, caused by a newly discovered coronavirus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2), continues to spread all around the world. Despite the emergency of COVID-19 worldwide, remdesivir is the only treatment that has been recently approved to treat the diseases, and other effective therapies are still lacking. SARS-CoV-2 may cause severe illness in 20% of patients. Based on available data, there is an association between interleukin-6 (IL-6) and severe COVID-19. Sarilumab is a fully human immunoglobulin G1 monoclonal antibody binding to both membrane-bound and soluble IL-6 receptors with high affinity and has been considered for off-label use in the treatment of COVID-19. Areas covered: The present article reviews recently published literature focusing on the pathophysiology of COVID-19 induced cytokine storm, the potential therapeutic role, and important clinical issues of sarilumab in the treatment of COVID-19 patients. Expert opinion: The off-label treatment administration is unavoidable in the critical situation of the COVID-19 pandemic. Further efforts should be directed to determine mechanisms of SARS-CoV-2 induced immune dysregulation as well as indications of sarilumab in the patients with COVID-19 to minimize concerns regarding its off-label administration.
Schlagwörter	covid19
Verlag	WHO
Dokumenttyp	Artikel
Anmerkung	WHO #Covidence: #915830
Datenquelle	COVID19

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Artikel ; Online: A Comprehensive Review on Sarilumab in COVID-19

Khiali, Sajad / Rezagholizadeh, Afra / Entezari-Maleki, Taher

Expert Opinion on Biological Therapy ; ISSN 1471-2598 1744-7682

2020

Schlagwörter	Clinical Biochemistry ; Pharmacology ; Drug Discovery ; covid19
Sprache	Englisch
Verlag	Informa UK Limited
Erscheinungsland	uk
Dokumenttyp	Artikel ; Online
DOI	10.1080/14712598.2021.1847269
Datenquelle	BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

Volltext online

Volltext online

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Kategorien

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED